In Plain English:
Vilon is a two-amino-acid chain (lysine + glutamic acid) originally isolated from the active fraction of Thymalin, the bovine thymus extract developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. As the simplest known bioregulatory peptide, it exerts outsized effects on the immune system by physically interacting with chromatin — the tightly wound DNA-protein complex inside ageing cells — and loosening regions that had become transcriptionally silent. In ageing immune cells, this allows previously repressed genes to be read again, restoring patterns of T-cell differentiation, cytokine balance, and anti-tumour surveillance that decline with age. Animal studies have documented spontaneous tumour reduction, lifespan extension of 20–40%, and suppression of chemically induced neoplasia. In vitro work in human THP-1 macrophages confirms it reduces TNF-α and IL-6 in response to bacterial challenge. In human skin fibroblast models it raises collagen type I and sirtuin-6 expression. Vilon has no western regulatory approval and is sold internationally as a research compound only.
Research Maturity
Animal / In Vitro (~35–50 peer-reviewed papers (1997–2025), mostly animal/in vitro; no human RCTs, single-group (Khavinson)+ Studies)
Focus
Cellular Regulation
Healthy Aging
Immunity
Origin
Identified as the primary immunomodulatory dipeptide (KE) within Thymalin (bovine thymic polypeptide extract) by V.Kh. Khavinson and V.G. Morozov at the Military Medical Academy, St. Petersburg, USSR. First characterised and independently synthesised circa 1993. Trademarked as Vilon; the sequence Lys-Glu was confirmed to account for the core T-cell-restoring activity of the parent thymus extract.
Mechanism
Penetrates cell membranes via receptor-independent mechanisms and binds directly to histone proteins (H1/H3) and double-stranded DNA at specific promoter regions. Core chromatin-level actions (Lezhava et al., 2004 — PMID 15105581): (1) induces deheterochromatinisation — unrolling of total and facultative heterochromatin; (2) reactivates ribosomal genes in nucleolus organiser regions; (3) releases genes repressed through euchromatin condensation in ageing lymphocytes; (4) preserves structural (pericentromeric) heterochromatin integrity. Downstream: stimulates thymocyte proliferation and CD4+/CD8+ T-cell maturation; increases CD5 expression on thymic lymphocytes; activates ERK1/2 (MAPK) phosphorylation and STAT1 signalling; reduces TNF-α and IL-6 production in LPS-activated macrophages; downregulates monocyte adhesion to activated endothelium; inhibits MMP-9 (matrix metalloproteinase-9) synthesis in ageing fibroblasts; raises collagen type I expression and sirtuin-6 (SIRT6) levels in human skin fibroblasts; modulates NF-κB to reduce mitochondrial inflammatory load.
Outcome
Spontaneous tumour incidence in CBA mice (reduced); maximum lifespan in mice (+20-40% mean, PMID 11140587); induced bladder tumour incidence in rats (75.5% → 56%, PMID 11785104); DMH-induced colon tumour incidence in mice (60% → 14.3%, PMID 16308980); ERK1/2 and STAT1 phosphorylation (THP-1 cells, PMID 35408963); TNF-α and IL-6 (LPS-activated macrophages); CD5+ lymphocyte differentiation (thymic cell culture, PMID 23486604); MMP-9 expression (ageing skin fibroblasts, PMID 27259496); collagen type I area (+83% in old fibroblast cultures); SIRT6 expression (1.6× young / 2.6× old fibroblasts); chromatin reactivation in aged lymphocytes (Biogerontology 2004, PMID 15105581).
